Socialiya - Entertainment. Knowledge. Community.
ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate...

BUSINESS NEWS May 30, 2026

ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic...

2 views 0 likes 0 comments
Share:
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic...

Author: Fierce Pharma

Read Original Article

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya